Apr 10, 2020

Added questions to “Psychotropic Drug Classes, MOA, and Names (Level 2)”. Merged broad-review tests “Epidemiology” and “Psychiatric DDx, Comorbidities, & Complications” together. Merged “Psychotropic Drug Classes, MOA, and Names (Level 2)”, “Psychotropic Drug Indications, Contraindications, Side Effects, and DDI”, and “Psychotropic Drug Dosing” together into “Psychopharmacology”.

Apr 5, 2020

Added new test “DSM-5 Criteria Disruptive, Impulse-Control, and Conduct Disorders”. Psychiatry resident level tests recategorized into “Broad Topic Review” vs “Specific Topic Review”. Edited questions for “Overview of Bipolar Disorder Management per CANMAT 2018 Guidelines”